- Mergers & acquisitions
- Equity capital markets
ETABLISSEMENTS FAUVET-GIREL is a company listed on the EURONEXT C market of EURONEXT Paris, which historically operated a railcar rental business as well as the management of a real estate portfolio.
After having sold all its assets, ETABLISSEMENTS FAUVET-GIREL has become a pure “shell company”, as the historical shareholders no longer wished to develop projects within the company.
On October 15, 2021, ADVANCED BIOLOGICAL LABORATORIES SA (ABL SA) acquired from several shareholders of ETABLISSEMENTS FAUVET-GIREL, various blocks of shares representing in total 96.69% of the capital.
ABL SA will file a simplified takeover bid with the Autorité des Marchés Financiers in accordance with the regulations in force. Once this transaction is completed, shareholders will be asked to approve the proposed transfer of ABL France SA (ABL France) and its American subsidiary to ETABLISSEMENTS FAUVET-GIREL.
ABL France is a company specialized in diagnostics for infectious diseases using genotyping. ABL France develops and markets proprietary genotyping diagnostic kits targeting chronic infectious diseases. ABL France developed the first high-tech genotyping products for AIDS, viral hepatitis and more recently, tuberculosis. ABL France is also developing products for the genotyping of Covid-19.
ATOUT CAPITAL advised the shareholders of ETABLISSEMENTS FAUVET-GIREL in this transaction. This type of transaction is a real alternative to an IPO and allows projects to be listed and thus use a wider range of financing tools.
This transaction is the 10th of this kind carried out by ATOUT CAPITAL’s teams on EURONEXT C and demonstrates once again ATOUT CAPITAL’s ability to identify and carry out complex stock market operations.